Healthcare [ 12/13 ] | Diagnostics & Research [ 56/164 ]
NASDAQ | Common Stock
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally.
The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics.
It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus.
It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions.
It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health.
Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | -0.01 Increased by +95.24% | -0.10 Increased by +90.00% |
| Mar 4, 24 | 0.04 Increased by +133.33% | 0.01 Increased by +300.00% |
| Nov 6, 23 | -0.03 Increased by +84.21% | -0.08 Increased by +62.50% |
| Aug 3, 23 | -0.08 Decreased by -300.00% | -0.08 |
| May 3, 23 | -0.21 Decreased by -600.00% | -0.19 Decreased by -10.53% |
| Feb 28, 23 | -0.12 Decreased by -500.00% | -0.16 Increased by +25.00% |
| Nov 1, 22 | -0.19 Decreased by -850.00% | -0.06 Decreased by -216.67% |
| Aug 4, 22 | 0.04 Decreased by -66.67% | 0.01 Increased by +300.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 202.20 M Increased by +11.59% | -26.00 M Increased by +52.47% | Decreased by -12.86% Increased by +57.40% |
| Dec 31, 23 | 196.60 M Increased by +10.57% | -31.20 M Increased by +26.24% | Decreased by -15.87% Increased by +33.29% |
| Sep 30, 23 | 191.90 M Increased by +22.70% | -61.30 M Decreased by -74.64% | Decreased by -31.94% Decreased by -42.34% |
| Jun 30, 23 | 183.50 M Increased by +2.34% | -116.10 M Decreased by -723.40% | Decreased by -63.27% Decreased by -704.56% |
| Mar 31, 23 | 181.20 M Increased by +9.88% | -54.70 M Decreased by -166.83% | Decreased by -30.19% Decreased by -142.83% |
| Dec 31, 22 | 177.80 M Increased by +10.57% | -42.30 M Decreased by -456.58% | Decreased by -23.79% Decreased by -403.36% |
| Sep 30, 22 | 156.40 M Decreased by -6.52% | -35.10 M Decreased by -242.68% | Decreased by -22.44% Decreased by -252.63% |
| Jun 30, 22 | 179.30 M Decreased by -5.33% | -14.10 M Decreased by -200.00% | Decreased by -7.86% Decreased by -216.90% |